RGC Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Regencell Bioscience Hldgs L (RGC) following the 2026 Q2 hedge fund 13F filings?

As of today, RGC has moved +8.3% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.6% for the XLV sector ETF — an outperformance of +7.7%. Since the quarter end (June 30, 2026), RGC gained -3.1% vs +6.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Regencell Bioscience Hldgs L (RGC)

36 + Investors. Track Smart Money conviction in RGC. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — RGC

Based on 37 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q

For 7 consecutive quarters, more hedge funds added RGC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

37 hedge funds hold RGC right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +185% more funds vs a year ago

fund count last 6Q

+24 new funds entered over the past year (+185% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 63% buying

29 buying17 selling

Last quarter: 29 funds were net buyers (15 opened a brand new position + 14 added to an existing one). Only 17 were sellers (7 trimmed + 10 sold completely). A clear majority buying is a strong confirmation signal.

➡️

Steady new buyers — ~15 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 10 → 6 → 17 → 15. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

📌

Mixed — 38% long-term, 43% new

■ 38% conviction (2yr+) ■ 19% medium ■ 43% new

Of the 37 current holders: 14 (38%) held >2 years, 7 held 1–2 years, and 16 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💎

Buying through price weakness — shares +119%, value -45%

Value

-45%

+118%

Last quarter: funds added +119% more shares while total portfolio value only changed -45%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📈

Growing discovery — still being found

10 → 10 → 6 → 17 → 15 new funds/Q

New funds entering each quarter: 10 → 6 → 17 → 15. A growing number of institutions are discovering RGC each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 56% veterans vs 41% newcomers

■ 56% veterans ■ 2% 1-2yr ■ 41% new

Entry-cohort mix of 41 holders: 23 (56%) are 2+ year veterans, 1 entered 1–2 years ago, and 17 (41%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 49% AUM from top-100 funds

49% from top-100 AUM funds

13 of 36 holders are among the 100 largest funds by AUM, controlling 49% of total institutional value in RGC. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

6.1

out of 10

Moderate Exit Risk

Exit risk score 6.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	36	32	12.5%
13F Shares	2M	749K	118.75%
Total Value	$10M	$18M	-45.34%
New Positions	15	17	-2
Increased Positions	13	7	+6
Closed Positions	10	4	+6
Reduced Positions	6	6	-
Total Calls	2	2	-
Total Puts	3	3	-
PUT/CALL Ratio	1.5	1.5	Bearish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

12.5%

13F Shares

749K

118.75%

Total Value

$10M

$18M

-45.34%

New Positions

-2

Increased Positions

Closed Positions

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

1.5

Bearish

Institutional Holders (2026 Q2)

36 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RGC. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 RGC holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Fox Run Management, L.L.C.	0.02%	20,691	$126K
2	Alyeska Investment Group, L.P.	0.01%	416,261	$2.5M
3	XTX Topco Ltd	0.00%	60,061	$366K
4	State of Wyoming	0.00%	4,070	$25K
5	Quadrature Capital Ltd	0.00%	41,750	$254K
6	Vident Advisory, LLC	0.00%	11,199	$68K
7	Aquatic Capital Management LLC	0.00%	2,058	$13K
8	CIBC Asset Management Inc	0.00%	15,292	$93K
9	Legal & General Group Plc	0.00%	128,000	$779K
10	Squarepoint Ops LLC	0.00%	22,036	$134K
11	EverSource Wealth Advisors, LLC	0.00%	498	$3K
12	Amundi	0.00%	47,159	$287K
13	Two Sigma Investments, LP	0.00%	14,406	$88K
14	Citadel Advisors LLC	0.00%	75,300	$459K
15	Federation des caisses Desjardins du Quebec	0.00%	2,803	$17K
16	Jane Street Group, LLC	0.00%	98,348	$599K
17	Bare Financial Services, Inc	0.00%	30	—
18	UBS Group AG	0.00%	43,208	$263K
19	Jane Street Group, LLC	0.00%	65,100	$396K
20	Larson Financial Group LLC	0.00%	168	$1K
21	Citadel Advisors LLC	0.00%	33,200	$202K
22	Susquehanna International Group, LLP	0.00%	47,700	$290K
23	Bell Investment Advisors, Inc	0.00%	20	—
24	Blue Trust, Inc.	0.00%	216	$1K
25	Susquehanna International Group, LLP	0.00%	23,129	$141K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Regencell Bioscience Hldgs L (RGC)

What does the Smart Money Trend signal show for RGC?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added RGC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RGC?

More buyers than sellers — 63% buying: Last quarter: 29 funds were net buyers (15 opened a brand new position + 14 added to an existing one). Only 17 were sellers (7 trimmed + 10 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for RGC holders?

Elite ownership — 49% AUM from top-100 funds: 13 of 36 holders are among the 100 largest funds by AUM, controlling 49% of total institutional value in RGC. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held RGC?

Mixed — 38% long-term, 43% new: Of the 37 current holders: 14 (38%) held >2 years, 7 held 1–2 years, and 16 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Regencell Bioscience Hldgs L (RGC) following the 2026 Q2 hedge fund 13F filings?

As of today, RGC has moved +8.3% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.6% for the XLV sector ETF — an outperformance of +7.7%. Since the quarter end (June 30, 2026), RGC has gained -3.1% vs +6.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Regencell Bioscience Hldgs L (RGC)

Smart Money Signals — RGC

Buying streak — 7 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +185% more funds vs a year ago

More buyers than sellers — 63% buying

Steady new buyers — ~15 new funds per quarter

Mixed — 38% long-term, 43% new

Buying through price weakness — shares +119%, value -45%

Growing discovery — still being found

Veteran-anchored — 56% veterans vs 41% newcomers

Elite ownership — 49% AUM from top-100 funds

Institutional Sentiment Summary — RGC

Hedge Fund Ownership: RGC

Market Analysis: RGC

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: RGC

Is It Too Late to Buy Regencell Bioscience Hldgs L (RGC) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: RGC

Statistics: RGC

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Regencell Bioscience Hldgs L (RGC)

Welcome to 13Foresight!